Skip to content

MaxCyte MXCT EPS (Basic)

EPS (Basic) at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
-$19.55-954%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$4.44+11.3%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$1.39+17.3%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$0.18-20.0%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$0.31-19.2%
PDE
Pro-Dex, Inc.PDEX
$1.23+23.0%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's EPS (basic)?
MaxCyte (MXCT) reported EPS (basic) of -$0.04 in Q1 2026.
How has MaxCyte's EPS (basic) changed year-over-year?
MaxCyte's EPS (basic) increased by 60.0% year-over-year, from -$0.10 to -$0.04.
What is the long-term trend for MaxCyte's EPS (basic)?
Over 4 years (2021 to 2025), MaxCyte's EPS (basic) has grown at a 18.2% compound annual growth rate (CAGR), from -$0.22 to -$0.43.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.